Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bunka just got voted in with 97% of the votes at the AGM. I guess you were one of the 3%.
Yes this is a nothing announcement and shows how full of crap these folks are
Becaue they aren't actually important or particularly good and the management has proven a disaster for years. You see this constantly. People care about management and capital management and this company is terrible at that and hasn't produced anything. The data they release from time to time isn't actually that good (if it was, others would take notice).
The way this stock trades is some folks buy on a hot tip after a paid article comes out, then they jump a bit and sell, and it just goes down as people give up before the next pump.
It's not that thigs aren't adding up, it's that nothing good will happen with the share price until they start making money. It's been too long so people gave up on buying before anything happens
http://anodgen.com/
Scroll down to see who Lexaria's US representative is, its Joseph Fanelli. He's also a technical advisor to anodgen. https://anodgen.com/?page_id=1120
@Mansax We're definitely not getting the inside scoop here.
Why do all these new agreements have very little effect on the share price and as important, the volume? Are these just head fakes by Bunka with other friendly miniscule companies looking for PR? Where's Altria, GW......, scooping this up at these levels? Something is not adding up.
Lexaria Grants License to AnodGen Bioceuticals
Wed, June 8, 2022, 8:00 AM
In this article:
LEXX
+4.15%
DehydraTECH Pharmaceutical License Issued for the European, Australian and New Zealand markets
Lexaria to receive royalty revenue from DehydraTECH product sales
KELOWNA, BC / ACCESSWIRE / June 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the awarding of a five-year, non-exclusive DehydraTECH license (the "License") from its wholly-owned subsidiary, Lexaria Pharmaceutical Corp. to AnodGen Bioceuticals ("AnodGen") of Ireland.
The awarded License is valid for the manufacturing and distribution of DehydraTECH processed cannabinoid active pharmaceutical ingredient ("API") powders within Europe including the UK, Australia and New Zealand; including pharmaceutical and medical product applications for psychoactive cannabinoids and medical product applications for non-psychoactive cannabinoids. Anodgen will pay royalty fees to Lexaria for all API powders sold that utilize the DehydraTECH technology. Anodgen has the right to manufacture and sell these API powders to third party companies for their own products that are designated by a national regulator as a medical product, drug, nutraceutical, pharmaceutical or biopharmaceutical, as applicable, under its cannabinoid product license rights.
"This strategic alliance with Lexaria Bioscience Corp. underscores the focus of Anodgen to ‘Bring Science to Life', in addition to our research and API's," said Dr Slimane Aboulkacem, Chairman and Founding Member of Anodgen Bioceuticals.
Dr Jeffrey Pruski, Anodgen's Chief Medical Officer and Founding Member mentioned that "the partnership with Lexaria will help bring research-based API's and technology to companies and people with superior bioavailability and enhanced absorption. This alliance will bring about change we will yet see in pharmacokinetics and formulation."
Consumer products purchased without physician or medical professional consultation are not permitted under the terms of this License. AnodGen is expected to have their new facility in Ireland fully operational later in 2022 and Lexaria recognizes the long-term potential for growth in the utilization of DehydraTECH across these pharmaceutical market opportunities.
About AndoGen Bioceuticals.
Anodgen Bioceuticals is a newly established contract manufacturing organization business that will manufacture and distribute active pharmaceutical ingredients for the pharmaceutical industry by focusing on world class research on pharmacognosy (plant-based medicine). Anodgen Bioceuticals mission is to "bring science to life" by developing a global, purpose-led, science-based company that specializes in pharmacognosy, active nutrition, health, and sustainable living. Anodgen Bioceuticals has global expertise and innovation to add value to science around plant derived medicine. More importantly, Anodgen specializes in sourcing and custom compound APIs of cannabinoids and other customized blends. The Company has recently signed two research MOUs with renowned U.S. universities to collaborate on research.
We need some bad news to get the price up, because good news ain't doing shit.
There's is also the expected royalty payments. The Japanese didn't sign this agreement with the expectation of not selling products.
"In addition to the Payments, Lexaria will also receive royalty revenue from DehydraTECH licensed product sales, the terms of which have been agreed to. Total revenue is expected to be significantly greater than the minimum Payments if Premier is capable of meeting its expected revenue targets. If Premier achieves even their worst-case projected penetration into the Japanese non-pharmaceutical CBD market, then based on their projections Lexaria could expect to receive annual payments of over $5 million by the fifth year of the contract."
Potential outcomes, expectations
There are 5mm outstanding shares and 200mm authorized!! Basically, the company can conitnue to just issue shares and dilute everyone (no reason to expect they would ever stop doing this as it's ALL they have really done over the ast few years).
If you invested around the Altria deal, you'd be down 90% and would need a 10x from here to break even...what are the chances you think that could EVER happen with this many shares authorized?
Hate to be a downer here, but there's not much reason to invest in this pile as long as Bunka is in charge...constant promises with nothing to show other than mostly useless new patents that he just uses to pretend he's making progress.
Japanese deal not that great
"In order to retain ongoing exclusivity, the negotiated minimum quarterly payments ("Payments") to Lexaria begin September 1, 2022 and, during the first five years of the Agreement, amount to US$4,527,500"
this is less than $1mm per year and it's only if the company want to retain exclusivity. Given Lexaria has no other potential deals on the horizon, they don't need to maintain exclusivity. So, in short, even if they make these payments, it doens't mean much for the company, and they aren't that likely to anyway.
Ted Ohashi Pg. 7
https://4495825a-d729-4d8f-ade8-e78f828e1c8d.usrfiles.com/ugd/449582_5fd3798e43074dacb8f1a381c974d835.pdf
Special Report
Important News from Lexaria Bioscience
There was some important news from Lexaria Bioscience (NASDAQ: LEXX) (NASDAQ: LEXXW)
that is all the more important because it seems to me the market missed the point.
(1) On June 2, 2022, LEXX announced it grant Valcon Medical, a DehydraTECH™ license
for medical cannabis applications, its first licensing agreement in Europe. Valcon
Medical is a European contract manufacturing organization specializing in the manufacturing of medical cannabis extracts for the European Union and the UK. Valcon is GMP certified and licensed under the Danish medical cannabis program to manufacture cannabis
products requiring physician-patient consultation. I think this is important because:
• Valcon is the most advanced medical cannabis manufacturer in its field in Europe and
leads the cannabis industry in manufacturing capacity and production of the highest quality
full spectrum extracts and API cannabinoid isolates.
• Valcon is supported by a shareholder group comprised of some of the leading cannabis
investment funds in the world, including Altitude Capital, Artemis Growth Partners, Enexis
AB, Greenfield Global Opportunities, and Nimb Capital.
• The license is non-exclusive and includes a combination of defined milestone fees payable
to Lexaria upon completion of batch validation and marketing authorization application approvals for the first DehydraTECH-enabled products for each of several product categories
as well as defined royalties payable to LEXX on revenues generated from Valcon's sales.
Conclusion: this may not be the most significant short term financial agreement but I think it is important for these reasons:
? It is another piece of evidence that DehydraTECH™ produces results that users assess
and decide it adds value.
? Valcon is an industry leader and others will be watching to see the ultimate results.
? It is a non-exclusive agreement which means separate agreements can be signed with
other companies that might decide to follow Valcon’s lead.
? The ideal end game is to reach the point where so many companies are using DehydraTECH™ others will be forced to use it if they are to be competitive. Each agreement of
this type brings LEXX one step closer to this objective.
(2) A far more important and financially rewarding agreement was announced effectively on June 3, 2022 as LEXX granted an exclusive license to Premier Wellness
Science for a strategic and long-term partnership in the Japanese market. Under the
agreement, Premier is purchasing the rights to DehydraTECH™ technology for the Japanese non-pharmaceutical market for use with CBD and hemp ingredients in oral liquid and
non-liquid products, as well as for topical, hair-care, lip-care and cosmetics products. I think
this agreement is important because:
8
• Lexaria and DehydraTECH™ finished first in a worldwide competition to evaluate advanced
delivery technology for active pharmaceutical ingredients run by Premier. In January 2022,
LEXX was contacted by Premier as the first step in the agreement that was just announced.
As Shinji Shosoyama said, "Premier conducted a global competition to evaluate the world's
most advanced molecule delivery technologies, and selected Lexaria's DehydraTECH
technology based on its superior performance and the extensive data available through
Lexaria's years of testing." For the first time, we have an independent commercial assessment of molecule delivery technologies and DehydraTECH™ prevailed. This lends significant credibility to the potential for DehydraTECH™ and LEXX.
• It is the largest financial commercial agreement for LEXX to date.
- In order to retain ongoing exclusivity, the minimum quarterly payments to LEXX amount
of US $4,527,500 during the first five years starting September 1, 2022.
- Assuming that Premier continues to submit all required payments, the license for the
Japanese market is perpetual.
- LEXX will receive royalty revenue from DehydraTECH licensed product sales, the
terms of which have been agreed to. If Premier achieves their minimum projections,
LEXX can expect annual payments of over $5 million by the fifth year of the contract.
- Lexaria and Premier have agreed to examine the possibility of research and development collaborations related to advanced formulation science. Premier and Parent have
long-established relationships with leading scientists in relevant fields in Japan.
• Premier is a wholly-owned subsidiary of Premier Anti-Aging (PAA) which is listed on the
Tokyo Stock Exchange Mothers division. PAA had revenues of approximately US $187
million in the first three quarters of fiscal 2021 with year-over-year revenue growth of
63.1%, strong profit margins from sales though over 45 product SKU's across four brands
sold in over 16,000 retail stores as well as directly through mail/web orders to over 2.6
million proprietary members. This is another major step up in the size and quality of a
DehydraTECH™ licensee.
• This financial information is more significant because:
- As fee and royalty income, these payments are far more significant that sales. They
represent gross profit because there is no cost of goods sold.
- One more agreement of this approximate financial impact would mean LEXX’s current
annual operating cash burn is covered.
- In fact, I suspect that if Premier should exceed their minimum expectations, it is possible
that the payments from this contract alone could do the job.
- LEXX’s business model is superior to other companies that may record higher revenues but negative gross profit.
• This agreement follows the awarding of two issued patents by the Japan Patent Office for
DehydraTECH™ technology. This confirms patent protection is a vital component of entering commercial agreements and, as I have said on several occasions, LEXX’s patent portfolio represents a valuable Intellectual Property asset.
9
• The overall Japanese cosmetics and personal products markets are estimated to be over
US $35 billion in annual sales.
Conclusion: I conclude these announcements are very significant despite the market’s apparent indifference. Over the past several months, investors have been critical of the slow pace at which LEXX’s
commercial business has developed. Management has said there was a need to develop information
that is required to conclude commercial contracts. It may be that LEXX has reached the tipping point
where we will see an increase in the number of commercial contracts concluded each year. Also, it
appears there is a clear trend toward potential commercial partners being well-established commercial
entities.
I bought LEXX shares because I believe the MC will eventually be worth many hundreds of millions and I haven't changed that belief. IMO The SP going down is merely a temporary setback to shake off weak hands. Hang on for more thrills and chills and hopefully profits! Eventually it won't matter if you bought LEXX for $2 pre-split.
What do you think about the new Japanese deal?
Come on Abundance88. All those amazing bargain buys you called out are extremely under water. (sadly your not alone I thought .30 cents pre split was a great buy lol).
If this keeps bleeding there will be another reverse split to keep it on Nasdaq.
Amazing low price with risk virtually eliminated. Bunka is delivering as promised. Bit of a wait to be sure but the waiting is over!!! Only sheep get the wool pulled over their eyes!
Pre split this is at .0726.
I was one of the biggest bulls in this stock and I am extremely disappointed
Besides basically one surge when the entire marijuana sector was rolling (and I believe they only had maybe one patent at this time) this stock has disappointed.
Back then many here including myself thought this company was going to $10+. (Lol now that would equal $300+)
I was wrong and feel awful for other friends I had invested into this company.
Bunka pulled the wool over my eyes that’s for sure.
Get your facts straight! The Market cap is currently 13M US https://www.google.com/finance/quote/LEXX:NASDAQ?sa=X&ved=2ahUKEwiNod7hipL4AhXGIzQIHTVnDzkQ3ecFegQIHhAg
The only fact, I repeat, the only fact you can truly believe is $2.20 a share and a 6 mil market cap, down over 80% in less than a year and closer to 90% from highs the year before. Have a great weekend!
Does that tell you anything about the facts???
TWO DOWN.
"What I can say is in three geographic areas around the world, Lexaria is making significant progress on commercial relationships that we are really excited about." CB
I'm Loving the latest news, Hopefully we will start to see the PPS rise and keep rising Lets GO! $LXRP woooops I mean $LEXX ;)
Now with this Japanese Deal that seems very possible.
I've been dreaming about Japan Tobacco (JTI). One of the big 4 tobacco companies, they do have a snus product but don't appear to have a pure nicotine pouch. A deal with them would be phenomenal.
I suppose when Altria makes their big move that would be the final straw!
I'd say "you must be new here", but I know you're not.
This has perhaps been one of the most consistent phenomena about Lexaria - its PPS is essentially inversely correlated to its news.
P&P would be pissed off if he won the powerball. "Now I need a lawyer and accountants, people are calling me all the time, God my life is hell"
Rome wasn't built in an hour and a half lol
pps wtf? Valcon (MEH - hard to tell) but Japan deal is very nice and thought pps would reflect it. I don't get it.
Worst case LEXX makes $5M US/yr from one deal ..and somehow this is bad. lol whatever.
Lexaria Grants Exclusive License to Premier Wellness Science Co., Ltd. for Strategic and Long-Term Partnership in the Japanese Market
Minimum payments due to Lexaria of US$4,527,500 over the first five years to retain exclusivity
Lexaria to receive royalty revenue from DehydraTECH product sales
Kelowna, British Columbia – June 2, 2022 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce a significant exclusive* commercial licensing agreement (the “Agreement”) in Japan with Premier Wellness Science Co., Ltd., (“Premier”).
Under the terms of the Agreement, Premier is purchasing the rights to DehydraTECH technology for the Japanese non-pharmaceutical market for use with CBD and hemp ingredients in oral liquid and non-liquid products, as well as for topical, hair-care, lip-care and cosmetics products. Premier is a wholly-owned subsidiary of Premier Anti-Aging Co., Ltd. (“Parent”) which is listed on the Tokyo Stock Exchange Mothers division with securities code 4934.
“Premier conducted a global competition to evaluate the world’s most advanced molecule delivery technologies, and selected Lexaria’s DehydraTECH technology based on its superior performance and the extensive data available through Lexaria’s years of testing,” said Shinji Shosoyama, CEO of Premier.
“Lexaria is delighted to be working with Premier Wellness Science which we expect will dominate the newly opening Japanese market for CBD-based products,” said Chris Bunka, CEO of Lexaria. “Premier and Lexaria share similar philosophies, such as the provision of world-leading products created through scientific advantages and placing the consumer’s needs ahead of our own. We could not have found a better partner with which to introduce DehydraTECH-enabled products to the Japanese markets.”
In order to retain ongoing exclusivity, the negotiated minimum quarterly payments (“Payments”) to Lexaria begin September 1, 2022 and, during the first five years of the Agreement, amount to US$4,527,500. Assuming that Premier continues to submit all required payments, the license for the Japanese market is perpetual.
In addition to the Payments, Lexaria will also receive royalty revenue from DehydraTECH licensed product sales, the terms of which have been agreed to. Total revenue is expected to be significantly greater than the minimum Payments if Premier is capable of meeting its expected revenue targets. If Premier achieves even their worst-case projected penetration into the Japanese non-pharmaceutical CBD market, then based on their projections Lexaria could expect to receive annual payments of over $5 million by the fifth year of the contract.
Premier’s Parent had revenues of approximately US$187,000,000 in the first three quarters of fiscal 2021 with year-over-year revenue growth of 63.1% and strong profit margins. Parent sells over 45 product SKU’s across four brands, and these products are sold in more than 16,000 retail stores as well as directly through mail/web order to over 2.6 million proprietary members. The overall Japanese cosmetics and personal products markets are estimated to be more than US$35 billion in annual sales.
As well, Lexaria and Premier have agreed to examine on a case-by-case basis the possibility of entering research and development collaborations related to advanced formulation science. Premier and Parent have long-established scientific relationships with some of the leading scientists in relevant fields in Japan.
This Agreement with Premier follows the awarding of two issued patents by the Japan Patent Office for DehydraTECH technology in Japan, strengthening Lexaria’s long-held beliefs that new patent protection is a vital component of entering commercial agreements.
*The exclusive rights are subject to two previously issued licenses for use of DehydraTECH in Japan, which remain valid. Lexaria will not be issuing any further licenses in Japan for non-pharmaceutical cannabinoid products.
About Premier Wellness Science Co., Ltd.
Premier Wellness Science Co., Ltd. is focused on the well-being of its customers that leads to good physical, mental and social health. The company seeks to achieve precision, individualized growth in health through a scientific approach to creating the highest performance products in the world.
About Premier Anti-Aging Co., Ltd.
Premier Anti-Aging Co., Ltd. engages in the planning, development, import/export, mail order, wholesale, and retail business of cosmetics and health foods. The company offers its cosmetic products under the DUO and CANADEL brands. It is also involved on the information provision and consulting services related to anti-aging, beauty, and health; research on management and beauty of beauty clinics, etc.; and marketing research and collection and analysis of various information. The company was founded in 2009 and is headquartered in Tokyo, Japan.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and over 50 patents pending worldwide. For more information, please visit www.lexariabioscience.com.
Sad that the stock is this low with back to back deals.
Notice how bunka tries to play the market announcing them separately trying to juice the stock.
Sick to my stomach how much faith I had in him and this company. Very expensive lesson learned.
New deal inked with $numbers
My bad, Maybe I should have said that they won't result in anything meaningful to shareholders.
Valcon Address shows impressively large bldg. https://www.google.com/maps/place/Industrivej+12,+3540+Lynge,+Denmark/@55.8305631,12.3043965,222a,35y,39.46t/data=!3m1!1e3!4m5!3m4!1s0x46524472bdfb03e5:0x3a9d604ac07fe5c5!8m2!3d55.8321866!4d12.3051294
Not the yellow bldg #10 but the red one #12 behind it!
More info on Valcon Medical's EU-GMP certification. These guys are for real. https://www.prnewswire.com/news-releases/valcon-medical-as-announces-receipt-of-eu-gmp-certification-and-start-of-commercial-production-for-pharmaceutical-grade-cannabis-concentrates-intermediary-products-and-medical-formulations-301317236.html
@chunkmuck That's just pure FUD
Pete Patterson is Bumkas golf partner, just like ohashi, making all these make belief deals that will never happen.
Good thing this deal is with reputable people!
Never wild about deals where there is no arms length and they feed their pockets multiple times. Do either company have any revenues of substance or can't find that out, since private? The more you love it, the more you gotta question, why.......$2.25?Show me the money!
Thanks Shawking. Pete Patterson sounds very knowledgeable. Very promising for Lexaria to get a foot in the door in the European market in it's infancy. Good interview on the video. Funny about the Kelowna connection too.
Pete Patterson started Vitalis in Kelowna, BC and Valcon gets their extraction equipment from Vitalis.
https://www.kelownadailycourier.ca/business_news/article_f5ce6d80-5e05-11e8-aa5b-2f674361596d.html
Pete Patterson CEO of Valcon interview
GMP Certified means hardly a garage based company!
Valcon Medical is a European contract manufacturing organization ("CMO"), specialized in the manufacturing of medical cannabis extracts for the European Union ("EU") and the UK. Valcon is GMP certified and licensed under the Danish medical cannabis program to manufacture cannabis products that require physician-patient consultation.
Followers
|
220
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
34625
|
Created
|
10/02/07
|
Type
|
Free
|
Moderators |
Lexaria Bioscience Corp. (CSE:LXX; OTCQX:LXRP) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.
Lexaria’s DehydraTECHTM delivery technology is protected by a robust suite of patents granted or pending worldwide and is proven effective in multiple international studies in greatly assisting rapidity and quantity of absorption of a range of lipophilic (i.e., fat-soluble), bioactive molecules. By significantly enhancing the performance and experience with oral ingestion, Lexaria’s DehydraTECH delivery technology offers a viable and often healthier alternative to other delivery methods for bioactive substances in widespread use today such as inhalational delivery through smoking.
Lexaria’s patented technology, DehydraTECH™ delivers these important benefits:
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners
Effects are felt within 15-20 min vs. 60-120 min.
Initial testing indirectly evidences DehydraTECH may deliver ingested molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects and reducing liver biotransformation.
Bio-absorption increases up to 3 – 10X, to equate or exceed that of other routes of administration like inhalational delivery.
Lexaria’s DehydraTECH™ is designed specifically for formulating and delivering lipophilic (i.e. fat-soluble) drug payloads. It is patented or patent-pending for use with a broad range of bioactive molecules, including but not limited to:
Lexaria Bioscience Corp. (“Lexaria”) has formed the Lexaria Nicotine Corp. as its exclusive worldwide nicotine business unit. More than 89% of all nicotine that is consumed worldwide is delivered through smoking cigarettes. Approximately 6,000,000 deaths per year around the world are attributed primarily to the delivery of nicotine through the act of smoking according to the Centers for Disease Control and Prevention. Of note: “…it is primarily the toxins and carcinogens in tobacco smoke – not the nicotine – that cause illness and death.” (U.K. National Institute for Health and Care Excellence [NICE]). As many as 69% of U.S. adult smokers want to quit smoking and 43% of US adult smokers have attempted to quit in any twelve-month period. Lexaria postulates that delivery of nicotine to satisfy current demand, utilizing our patented DehydraTECH technology in common food and consumer product formats, could shift demand away from smoking cigarettes. However, ingestion of nicotine is challenging because it is poorly tolerated by the human gastrointestinal system and then significantly metabolized by the liver, thereby diminishing its overall effectiveness through edibles. Lexaria’s DehydraTECH technology offers a means to formulate ingestible product formats of nicotine and/or its analogs with higher bioavailability performance possibilities due to the benefits of our technology.
Lexaria is developing a patent suite with supporting intellectual property in the pharmaceutical sector that will supply significant long-term strategic growth potential. Lexaria Pharmaceutical Corp. is the 100%-owned subsidiary that has obtained exclusive worldwide rights to Lexaria’s patent portfolio related to pharmaceutical applications. Currently within this business unit resides the IP for Non-Steroidal Anti-Inflammatories (NSAIDs), Vitamins, hormone treatments utilizing estrogen or testosterone, phosphodiesterase inhibitors (PDE5). Additional molecules of interest could be added to this unit over time.
According to Statista.com, the global pharma industry was worth $1,105 billion in 2016, and the US pharma industry alone spent over $71 billion in 2017 on R&D: a larger R&D expenditure than the entire gross revenues of many other business sectors.. Lexaria Pharmaceutical Corp. is implementing a strategy of reinforcing its IP-suite to sufficient degree to begin partnering within this dynamic industry.
The Lexaria Hemp Co. holds exclusive global rights to the Lexaria patent portfolio related to hemp-based applications. Lexaria’s DehydraTECH technology is designed to deliver functional ingredients within hemp in oral product formats with significantly enhanced palatability, speed of effectiveness and potency as a viable and healthier alternative to conventional inhalational (i.e. smoking or vaping) administration practices. Extensively evaluated through invivo, invitro, and human clinical studies, one of the most extensive databases in the world has been collected by Lexaria related to hemp-based ingredients empowered with our DehydraTECH technology. In 2018, the World Anti Doping Agency (WADA) for the first time ever exempted cannabidiol from hemp from its list of restricted substances on its International Standards Prohibited List of substances.
Lexaria CanPharm Corp, a Canadian corporation, owns exclusive global rights to Lexaria’s intellectual property as it is applied to psychotropic bioactive molecules that act upon human CB1 and CB2 receptors in those areas of the world where it is permissible to do so. Substances that act upon these receptors and systems in the human body that affect pain, inflammation, anxiety and depression, and have also been shown to have utility against cancer and neurodegenerative conditions. Lexaria’s ground-breaking 2018 research that proved many-fold improvements in delivering an active ingredient across the blood-brain-barrier could have disruptive potential within this business sector as well as all others where Lexaria is active.
The safety and effectiveness of Lexaria’s DehydraTECH™ technology has been studied in a series of controlled and well designed in vitro and in vivo human focus studies, examining factors such as total bioabsorption directly and indirectly through surrogate biomarkers, time to onset of effectiveness, flavor appeal and quality of effectiveness. Studies to-date have focused on cannabinoid applications where Lexaria is most advanced commercially, although research is underway for the other bioactive compounds named in Lexaria’s patent portfolio and described under Commercial Applications.
Pre-Clinical Research into Lexaria’s DehydraTECH™
An in vitro absorption study was performed to assess unidirectional CBD permeability using a human epi-intestinal tissue model with various formulations in the presence of simulated intestinal fluid. The study was designed to, as closely as possible, mimic intestinal absorption as it would occur in a live subject. Samples of Lexaria’s commercially available CBD-fortified ViPova™ black tea were administered in the model compared with concentration-matched CBD control preparations that lacked Lexaria’s patented formulation and process enhancements. The study showed as much as a 499% improvement, on average, in intestinal tissue permeability with the ViPova™ black tea formulation relative to a concentration-matched CBD control preparation without any Lexaria technology enhancements. The study also showed a 325% improvement, on average, in intestinal tissue permeability comparing the ViPova™ black tea preparation to a concentration-matched CBD control preparation that utilized Lexaria`s dehydration synthesis processing methodology but lacked its fatty acid ingredient incorporation, demonstrating the power of the Lexaria technology as a whole (see Figure 1).
Following this study, a series of independent, well designed, well controlled human focus studies were undertaken corroborating Lexaria’s in vitro performance findings. A study in healthy volunteers (n=6) suggested as much as a 5-10X increase in CBD absorption, which was assessed indirectly through measurement of the increase in salivary nitric oxide as a directly proportional surrogate biomarker, with onset of action in as little as 15-30 minutes. In all cases, the maximum increased level of salivary nitric oxide remained evident at the 60-minute end period of this particular test. Further testing is required to determine the full duration of elevated nitric oxide levels.
Thereafter, a blinded human focus study was conducted to evaluate the performance of THC-infused chocolates formulated using Lexaria’s DehydraTECH™ technology. This study compared the performance of the THC-infused chocolates powered by Lexaria’s technology to concentration matched THC-infused chocolates formulated using a commercial dextrin absorption enhancer. The subjects (n=12) that participated in this study indicated a clear preference on taste and overall effectiveness with the chocolates formulated using Lexaria’s technology, and onset of effectiveness was again observed very quickly, in as little as 15-20 minutes.
Lexaria Bioscience Corp’s disruptive new patented technology DehydraTECH™ is available to be licensed.
DehydraTECH can be used to improve existing products or to create new products. It is suitable for use with a wide range of consumer product formats including:
DehydraTECH is designed to be effective in delivering most fat-soluble molecules through the human gastrointestinal system and has also demonstrated affinity for transdermal applications and even effectiveness in crossing the blood-brain-barrier once within blood plasma. Lexaria has, or is conducting, in vitro, in vivo and human clinical testing, including pharmacokinetic data gathering, for the delivery of API’s through ingestible means. Test data has consistently pointed to reduced time required to enter the bloodstream, increased absorption rate, and reported improvements in taste and smell of edible products.
Contact us today to speak about your licensing needs at ablanchard@lexariabioscience.com
Terms and rights associated with our licensing opportunities are discussed on an individual basis.
Lexaria’s typical approach to working with a new prospective licensee is to effect confidentiality terms and then collaborate with the license prospect under a non-binding letter of intent to evaluate the feasibility and applicability of the Lexaria DehydraTECH technology for the license prospect`s needs. Following this, if the license prospect is satisfied with the performance enhancements delivered by the DehydraTECH technology, Lexaria then seeks to transition to a definitive fee bearing agreement structure between it and the new licensee.
We will license our technology in any of the more than 40 countries around the world where the DehydraTECH is patented or patent-pending. Licensees can feel confident that Lexaria’s extensive IP portfolio – constantly expanding – will help to provide a competitive edge and protection against inferior methodologies or older, outdated technology.
If your company works in a different but related field, please contact us if you’d like to conduct research on applicability for your specific application.
Licensees should also always remember that DehydraTECH costs less than a penny per serving to implement – sometimes a bare fraction of a penny. Licensees may experience an increase in market share or an increase in pricing power as a result of offering their customers superior delivery characteristics. Customers are loyal to the improved performance of DehydraTECH based products.
DehydraTECH is one of the world’s ONLY delivery technologies that does not require the addition of chemicals or intimidating, complex ingredients requiring disclosure on a food label. DehydraTECH works with commons GRAS ingredients that can be organic, gluten-free, and dairy free.
If your company works in a different but related field, please contact us if you’d like to conduct research on applicability for your specific application.
Masks taste/odor
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners.
Reduces time of onset
Effects are felt within 15-20 min vs. 60-120 min.
Increases bio-absorption
Increases bio-absorption by 2 – 10x, to equate or exceed that of other routes of administration like inhalational delivery.
Avoids first-pass liver metabolism
Testing has evidenced that DehydraTECH may deliver molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects. More recent testing in animals even demonstrated an ability to cross the blood-brain-barrier to a degree previously thought not possible.
Interview with CEO Chris Bunka
https://youtu.be/9bRSWYKIEL8
New Enhanced DehydraTECHTM formulation delivers 8X more CBD into blood and over 19X more CBD into brain tissue than standard industry formulations.
Kelowna, British Columbia – June 4, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, has discovered improved performance characteristics of a new version of the DehydraTECHTM delivery platform initially suitable for use in solid oral dosage forms like capsules, tablets and pills for the pharmaceutical, medical, and supplement markets. Lexaria’s innovative use of a naturally sourced formulation enhancement more than doubles DehydraTECH’s absorption performance compared to previous DehydraTECH results demonstrated to-date. The Company has filed new patent applications related to the recent innovations.
BACKGROUND
On March 20, 2019 Lexaria announced it was beginning a series of animal studies with multiple objectives, including evaluating enhanced DehydraTECH formulations that might offer improved performance. Copious data streams have been generated from these tests and continue to be analyzed.
In this arm of animal study, Lexaria tested its DehydraTECH delivery technology with compounds postulated to behave in a synergistic fashion for enhancement of gastro-intestinal absorption, which resulted in significantly enhanced DehydraTECH performance (“Enhanced DehydraTECH”).
Of note, the new Enhanced DehydraTECH and its improved performance is separate and distinct from the nanotech improvement techniques recently announced by the Company.
TEST RESULTS
In each arm of the Lexaria animal studies, 10 male Sprague-Dawley rats were administered an identically sourced CBD at a rate of 25mg per kg of bodyweight. Delivery of CBD into the bloodstream was measured at 2; 4; 6; 8; 12; 15; 30; 45; and 60 minutes after dosing. DehydraTECH-enabled CBD was measurable in animal blood within 2 to 4 minutes after dosing.
On May 15, 2019 the Company reported that DehydraTECH achieved a CBD blood concentration level that was 475% more than a generic industry medium chain triglyceride (“MCT”) coconut-oil formulation 15 minutes after dosing. Today, the Company reports that Enhanced DehydraTECH led to 811% more CBD delivery into blood than generic industry MCT coconut-oil formulations (p=0.00008); and 110% more CBD into blood than DehydraTECH in its traditional format (p=0.02).
Also of note is that both traditional DehydraTECH and Enhanced DehyraTECH delivered maximum blood concentration levels prior to the 60-minute end-of-test, with levels tapering off thereafter. The DehydraTECH technology therefore demonstrates both fast onset and fast offset as tested which is of interest for dose titration purposes when repeated dosing is desired.
CONCLUSION
DehydraTECH’s in its traditional format has been used commercially by the Company since 2014; and by the Company’s technology licensees since 2016. Lexaria has consistently introduced leading innovation for oral cannabis formats such as capsules, beverages and edibles, with a focus on the consumer experience as measured by qualities such as taste, rapidity of onset and offset, and reliability of effect. Unique among the cannabis industry, DehydraTECH has proven itself equally transformative in other sectors such as the nicotine industry where Lexaria has licensed its technology to one of the largest nicotine products companies in the world.
Enhanced DehydraTECH seems particularly adept at delivering previously unreachable quantities of CBD across the blood brain barrier and into brain tissue; more so than even the most advanced nanotech as previously reported utilized in these studies. Since most human receptor cells of the CB1 variety and otherwise that are associated with the psychotropic effects of cannabinoids are located within the brain these findings significantly expand upon the power of Lexaria’s technology to reach the target site of action for these purposes.
With this new innovation, Lexaria is establishing new performance thresholds for drug delivery technology, with tested performance of 8x (blood plasma) and more than 19x (brain tissue) of generic industry formulations. The Company intends to perform further studies to fully characterize Enhanced DehydraTECH and will work throughout 2019 to optimize implementation into the best product applications for use by its licensees.
The animal test results announced to date have led to additional new patent applications based on the positive performance results achieved. The specific nature of enhanced DehydraTECH shall remain undisclosed for proprietary reasons until the new patent filings are published. Although the current tests were limited to CBD absorption, Lexaria expects knowledge from the current innovation to apply equally to tetrahydrocannabinol (THC) as well to enhance formulation innovation for nicotine and various pharmaceutical compounds already named within the Lexaria patent suite.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |